Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siRNA targeting RACGAP1
- Development stage
- Preclinical
- Lead developer
- National Cancer Centre Singapore
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
siRNA targeting RACGAP1 is a therapeutic modality designed to silence the expression of the Rac GTPase-activating protein 1 (RACGAP1) gene through RNA interference. RACGAP1 is a key regulator of cytokinesis and has been identified as a significant prognostic biomarker for recurrence in hepatocellular carcinoma (HCC). Preclinical research indicates that the use of RACGAP1-specific siRNA in high-expression HCC cell lines inhibits cell migration and invasiveness by down-regulating mitotic and DNA damage response molecules such as PRC1, AURKB, and CDC2. This approach aims to mitigate the aggressive phenotype of HCC and potentially improve survival outcomes in patients at high risk for post-resection recurrence.
- Other names
- RACGAP1 siRNARACGAP-1 siRNARACGAP 1 siRNAanti-RACGAP1 siRNAanti-RACGAP-1 siRNAanti-RACGAP 1 siRNA
02
Targets
GEF/GAP (Ras GEF / GAP family)
Beyond the preview
Go deeper on siRNA targeting RACGAP1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siRNA targeting RACGAP1.